Back to Newsroom
Back to Newsroom

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CORT, FSNN and BSX

Friday, 10 May 2019 05:30 PM

The Klein Law Firm

Topic:
5

NEW YORK, NY / ACCESSWIRE / May 10, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Corcept Therapeutics Incorporated (NASDAQCM: CORT)
Class Period: August 2, 2017 to February 5, 2019
Lead Plaintiff Deadline: May 13, 2019

The lawsuit alleges Corcept Therapeutics Incorporated made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) the Company had improperly paid doctors to promote its drug Korlym; (2) the Company aggressively promoted Korlym for off-label uses; (3) the Company's sole specialty pharmacy was a related party; (4) the Company artificially inflated its revenue and sales using illicit sales practices through a related party; (5) such practices are reasonably likely to lead to regulatory scrutiny; and (6) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Get additional information about the CORT lawsuit: http://www.kleinstocklaw.com/pslra-1/corcept-therapeutics-incorporated-loss-submission-form?id=1477&from=1

Fusion Connect, Inc. (OTCMKTS: FSNN)
Class Period: August 14, 2018 to April 2, 2019
Lead Plaintiff Deadline: June 17, 2019

The complaint alleges that Fusion made materially false and misleading statements, later admitting that the process used by certain of its Birch subsidiaries for capitalizing costs associated with the customer on-boarding process and the related judgments and estimates were not designed with sufficient precision, leading to an overstatement of the Company's earnings (or net loss) of between $1.7 million and $2.3 million in the quarter ending on June 30, 2018, and between $3.4 million and $4.1 million in the quarter ending September 30, 2018.

Get additional information about the FSNN lawsuit: http://www.kleinstocklaw.com/pslra-1/fusion-connect-inc-loss-submission-form?id=1477&from=1

Boston Scientific Corporation (NYSE: BSX)
Class Period: February 26, 2015 to April 16, 2019
Lead Plaintiff Deadline: June 24, 2019

Throughout the class period, Boston Scientific Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Boston Scientific's surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse ("POP") were unsafe; (ii) accordingly, Boston Scientific's continued marketing and sales of these devices in the United States was unlikely to be sustainable; (iii) separately, the Company had sold vaginal mesh implants containing counterfeit or adulterated resin products imported from China; (iv) the foregoing conduct subjected the Company to a heightened risk of regulatory scrutiny and/or government investigations; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Get additional information about the BSX lawsuit: http://www.kleinstocklaw.com/pslra-1/boston-scientific-corporation-loss-submission-form?id=1477&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

Topic:
5
Back to newsroom
Back to Newsroom
Share by: